NCT04682327

Gut Microbiota and Cancer Immunotherapy Response

Observational Study on the Relationship Between Gut Microbiota and Immunotherapy Response of Non-small Cell Lung Cancer

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 50 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study will analyze the composition and diversity of the gut microbiota of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) through metagenomic high-throughput sequencing methods, and explore the relationship between the gut microbiota and anti-PD-1/PD-L1 treatment response. This study will further understand the influence and mechanism of the gut microbiota on tumor immunotherapy, and will provide new ideas and theoretical basis for improving the efficacy of tumor immunotherapy by targeting the gut microbiota in the clinic, and benefit more NSCLC patients.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
OTHER	Response to anti-PD-1/PD-L1	Response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.
OTHER	Non-response to anti-PD-1/PD-L1	Non response to anti-PD-1/PD-L1, after 4 cycles of anti-PD-1/PD-L1 treatment.

Timeline

• Start date: 2021-08-12
• Primary completion: 2022-12-30
• Completion: 2022-12-30
• First posted: 2020-12-23
• Last updated: 2021-08-13

Locations

1 site across 1 country: China